primary and other outcomes dream n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Primary and Other Outcomes: DREAM PowerPoint Presentation
Download Presentation
Primary and Other Outcomes: DREAM

Loading in 2 Seconds...

play fullscreen
1 / 5
clay

Primary and Other Outcomes: DREAM - PowerPoint PPT Presentation

75 Views
Download Presentation
Primary and Other Outcomes: DREAM
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Primary and Other Outcomes: DREAM Data are number (%). *Rows are not mutually exclusive for components of the composite—if a participant had more than one component of the composite then they are counted in the relevant row. †Regression implies achieving a normal fasting glucose concentration (as defined in both rows) and 2-h plasma glucose level. FPG = fasting plasma glucose. OGTT = oral glucose tolerance test. DREAM investigators. Lancet 2006;368:1096-1105.

  2. Primary and Other Outcomes: DREAM(cont’d) Data are number (%). *Rows are not mutually exclusive for components of the composite—if a participant had more than one component of the composite then they are counted in the relevant row. †Regression implies achieving a normal fasting glucose concentration (as defined in both rows) and 2-h plasma glucose level. ‡Defined as acute treatment with at least two of the following criteria: typical signs and symptoms, typical radiological evidence, use of diuretics, vasodilators, or inotropes. DREAM investigators. Lancet 2006;368:1096-1105.

  3. Adverse Events, Hospitalization, and Death: ADOPT † P<0.05 for the comparison between this treatment group and the rosiglitazone group; ‡ P<0.01 for the comparison between this treatment group and the rosiglitazone group. ADOPT study group. N Engl J Med 2006;355:2427-2443.

  4. Laboratory Assessment and Concomitant Use of Cardiovascular Drugs: ADOPT ¶ All laboratory values are mean values at 4 years; † P<0.05 for the comparison between this treatment group and the rosiglitazone group; ‡ P<0.01 for the comparison between this treatment group and the rosiglitazone group. ADOPT study group. N Engl J Med 2006;355:2427-2443.

  5. Rates of Myocardial Infarction and Death from Cardiovascular Causes Nissen and Wolski. N Engl J Med 2007;356:2457-2471.